We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05548296
Recruitment Status : Recruiting
First Posted : September 21, 2022
Last Update Posted : January 26, 2023
Sponsor:
Collaborator:
GOG Foundation
Information provided by (Responsible Party):
Acrivon Therapeutics

Brief Summary:
This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with low dose gemcitabine in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSignature® test status.

Condition or disease Intervention/treatment Phase
Platinum-resistant Ovarian Cancer Endometrial Adenocarcinoma Urothelial Carcinoma Drug: ACR-368 Drug: Gemcitabine Diagnostic Test: OncoSignature Phase 1 Phase 2

Detailed Description:

Participants will be selected for predicted efficacy of ACR-368 using the OncoSignature® Companion Diagnostic test. Participants will be allocated to one of 2 arms based on OncoSignature result:

Arm 1: OncoSignature Positive tumors

Arm 2: OncoSignature Negative or Unevaluable tumors

Participants in Arm 1 will receive ACR-368 as monotherapy. Participants in Arm 2 will receive the combination of ACR-368 and low-dose gemcitabine. Participants in both arms will be treated until disease progression, unacceptable toxicity or any criterion for stopping the study drug or withdrawal from the trial occurs.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 333 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Participants with an OncoSignature positive test will enter a Phase 2 study that will assess the efficacy of ACR-368 as monotherapy in each of the 3 tumor types, ovarian, endometrial, and urothelial carcinomas. Participants with an OncoSignature negative test will be entered in a Phase 1b study to assess the safety of the combination of ACR-368 and escalating doses of low dose gemcitabine (LDG) in each of the 3 tumor types. When the recommended Phase 2 (RP2D) dose is determined, participants will be entered in an exploratory Phase 2 study to assess the efficacy and safety of ACR-368 and the RP2D of LDG in each of the 3 tumor types.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination With Gemcitabine in Adult Subjects With Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status
Actual Study Start Date : August 29, 2022
Estimated Primary Completion Date : July 31, 2026
Estimated Study Completion Date : December 31, 2027


Arm Intervention/treatment
Experimental: OncoSignature Positive Tumors
In Arm 1, participants with an OncoSignature Positive test will enter a Phase 2 Simon 2-Stage Study that will assess the efficacy of ACR-368 as monotherapy in each of the 3 cohorts of participants (ovarian, endometrial, and urothelial).
Drug: ACR-368
ACR-368 is an experimental drug
Other Name: prexasertib

Diagnostic Test: OncoSignature
Biomarker profile based on prediction of drug sensitivity performed on biopsy tissue

Experimental: OncoSignature Negative or Unevaluable test
In Arm 2, participants with an OncoSignature Negative or Unevaluable test will receive the combination of ACR-368 and Low Dose Gemcitabine (LDG). The Phase 1b portion will allow participants with OncoSignature Negative or Unevaluable tumors to be enrolled, while the Phase 2 portion will only enroll participants with OncoSignature Negative tumors. A Phase 1b Study will assess the safety of the combination of ACR-368 and escalating doses of LDG in participants with any of the 3 tumor types (ovarian, endometrial, and urothelial). The Phase 1b Study will determine the recommended Phase 2 dose (RP2D) of LDG. When determined, a Phase 2 Exploratory Study will be initiated to assess the efficacy and safety of the combination of ACR-368 and the RP2D of LDG in each of the 3 cohorts of participants (ovarian, endometrial, and urothelial).
Drug: ACR-368
ACR-368 is an experimental drug
Other Name: prexasertib

Drug: Gemcitabine
Gemcitabine is a standard of care given at a low dose in combination with the experimental drug ACR-368

Diagnostic Test: OncoSignature
Biomarker profile based on prediction of drug sensitivity performed on biopsy tissue




Primary Outcome Measures :
  1. Arm 1 Monotherapy: Anti-tumor activity of ACR-368 in Ovarian, Endometrial, and Urothelial Cohorts [ Time Frame: Response will be assessed every 8 weeks from baseline through 2 years or death. ]
    Assess Objective Response Rate (ORR) per RECIST v1.1 by computed tomography or magnetic resonance imaging for the number of participants with a partial or complete response.

  2. Arm 2 Phase 1b: Adverse Events (AEs) for ACR-368 in combination with LDG [ Time Frame: AEs will be assessed from baseline through 2 years or death. ]
    Safety will be assessed by the incidence of AEs characterized overall and by type, incidence, severity graded according to NCI CTCAE v5.0, seriousness, and relationship to study treatment.

  3. Arm 2 Phase 1b: Determine the RP2D of LDG [ Time Frame: AEs will be assessed from first dose of LDG for 28 days for each subject in a cohort. ]
    The RP2D will be evaluated by the incidence of DLT events per dose level

  4. Arm 2 Exploratory Phase 2: Anti-tumor activity of ACR-368 plus LDG in Ovarian, Endometrial and Urothelial Cohorts [ Time Frame: Response will be assessed every 8 weeks from baseline through 2 years or death. ]
    Assess Objective Response Rate (ORR) per RECIST v1.1 by computed tomography or magnetic resonance imaging for the number of participants with a partial or complete response.


Secondary Outcome Measures :
  1. Arm 1: Number of subjects with confirmed OncoSignature thresholds for enrichment of ACR-368 monotherapy responders [ Time Frame: Baseline to first post treatment imaging at 8 weeks ]
    Response data including tumor shrinkage at first imaging and progression by computed tomography or magnetic resonance imaging for the first 12 participants in each tumor type

  2. Arm 1: Adverse Events (AEs) for ACR-368 monotherapy [ Time Frame: AEs will be assessed from baseline through 2 years or death. ]
    Safety will be assessed by the incidence of AEs characterized overall and by type, incidence, severity graded according to NCI CTCAE v5.0, seriousness, and relationship to study treatment.

  3. Relative dose intensity of ACR-368 [ Time Frame: First dose of ACR-368 in first cycle to dose on day 15 of second cycle of administration ]
    Assess the ratio of cumulative administered dose to the planned dose for first 2 cycles

  4. Arm 1: Limited pharmacokinetic (PK) testing in participants with Ovarian Carcinoma [ Time Frame: Dose of ACR-368 at day 1 and day 15 of first cycle ]
    Cmax will be assessed in the first cycle at baseline, end of infusion, hour 2 and hour 4

  5. Arm 2: Limited pharmacokinetic (PK) testing of ACR-368 in combination with LDG in all participants in Phase 1b [ Time Frame: Dose of ACR-368 at day 1 and day 15 of first cycle ]
    Cmax will be assessed in the first cycle at baseline, end of infusion, hour 2 and hour 4

  6. Overall Survival (OS) [ Time Frame: Up to 2 years ]
    The time from baseline until date of death

  7. Duration of Response (DOR) [ Time Frame: Up to 2 years ]
    The time from initial response until investigator assessed progressive disease for all subjects who achieve a confirmed objective response.

  8. Progression-free Survival (PFS) [ Time Frame: Up to 2 years ]
    The time from baseline until second disease progression or death whichever occurs first.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criterial: General

  1. Participants who are 18 years of age or older at time of consent.
  2. Participant must be able to give signed, written informed consent.
  3. Participant must have histologically confirmed, locally advanced (ie, not amenable to curative surgery and/or radiation therapy) or metastatic cancer that has progressed during or after at least 1 prior therapeutic regimen.
  4. Participant must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria (by local Investigator) (Eisenhauer, 2009). Participant must have radiographic evidence of disease progression based on RECIST criteria following the most recent line of treatment. Biochemical recurrence (eg, CA-125 in ovarian carcinoma) only is not considered as disease progression.
  5. Participant must be willing to provide tissue from a newly obtained tumor biopsy from an accessible tumor lesion not previously irradiated. Newly obtained is defined as a specimen obtained up to 12 weeks prior to initiation of treatment on Day 1 if no intercurrent systemic therapy in the interval. For biopsies obtained prior to the signing of the consent, Investigators should contact the Medical Monitor to confirm sample will be acceptable.
  6. Participant must be willing to provide an archival tumor tissue block or at least 20 unstained slides, if available.
  7. Participant must have stabilized or recovered (Grade 1 or baseline) from all prior therapy related toxicities, except as follows: Alopecia is accepted. Endocrine events from prior immunotherapy stabilized at ≤ Grade 2 due to need for replacement therapy are accepted (including hypothyroidism, diabetes mellitus, or adrenal insufficiency). Neuropathy events from prior cytotoxic therapies stabilized at ≤ Grade 2 are accepted.
  8. Participant must have an Eastern Cooperative Oncology Group Performance Status 0 or 1.
  9. Participant must have an estimated life expectancy of longer than 3 months.
  10. Participant must have adequate organ function at Screening, defined as: Absolute neutrophil count > 1500 cells/µL without growth factor support within 1 week prior to obtaining the hematology values at Screening. Hemoglobin ≥ 9.0 g/dL without transfusion or growth factor support within 2 weeks prior to obtaining the hematology values at Screening. Platelets ≥ 100,000 cells/µL without transfusion within 1 week prior to obtaining the hematology values at Screening. Calculated creatinine clearance ≥ 30 mL/min as calculated by the Cockcroft Gault formula. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN); ≤ 5 × ULN if liver metastases are present. Total bilirubin ≤ 1.5 × ULN not associated with Gilbert's syndrome. If associated with Gilbert's syndrome ≤ 3 x ULN is acceptable. Serum albumin ≥ 3 g/dL.
  11. Participant must have adequate coagulation profile as defined below (including if receiving anticoagulation therapy): Prothrombin time within the ULN. Activated partial thromboplastin time within the ULN. If the patient is anticoagulated, must be on a stable dose of anticoagulant for ≥ 1 month.

Tumor Specific Inclusion Criteria

For Ovarian Carcinoma:

  1. Participant must have histologically documented, platinum resistant, advanced (metastatic and/or unresectable) high-grade serous/endometrioid ovarian, primary peritoneal, or fallopian tube cancer. Platinum-resistant disease, defined as progression or relapse within 6 months after the completion of platinum-based therapy, is eligible. Primary platinum refractory disease, defined as progression while on the upfront platinum-based therapy, is not eligible.
  2. Participant must have received at least 1 but no more than 6 prior lines of systemic therapy, including at least 1 line of therapy containing platinum derivative and taxane, and single-agent therapy must be appropriate as the next line of treatment:
  3. Participant must have had prior bevacizumab or did not receive bevacizumab based on Investigator judgment (see Section 2.1.1).

For Endometrial Carcinoma

  1. Participant must have histologically documented, high-grade endometrial adenocarcinoma.

    1. All Grade 3 International Federation of Gynecology and Obstetrics epithelial endometrial histologies are eligible including: endometrioid, serous, and clear-cell carcinoma.
    2. Carcinosarcoma is eligible. Enrollment of participants with this histology will be capped at 5% for each cohort.
    3. Participant must have no more than 3 prior lines of therapy in the recurrent setting, including platinum-based chemotherapy for subtypes of endometrial adenocarcinoma where it is a standard of care.
  2. Participant must have documented failure or ineligibility (based on Investigator judgement) for prior anti-programmed cell death protein 1/anti-programmed death-ligand 1 (PD 1/PD L1) immunotherapy as single agent or in combination with lenvatinib for advanced/metastatic disease. Prior combination of PD 1/PD L1 inhibitor and vascular endothelial growth factor tyrosine kinase inhibitor is acceptable.

For Urothelial Carcinoma

  1. Participant must have histologically documented, advanced (metastatic and/or unresectable) urothelial carcinoma. Variant histology is allowed as long as the tumor is predominantly urothelial.
  2. Participants must have:

    1. Received a platinum containing regimen (cisplatin or carboplatin) in the metastatic/locally advanced, neoadjuvant, or adjuvant setting. If platinum was administered in the adjuvant/neoadjuvant setting, participant must have progressed within 12 months of completion.
    2. Failed or have been ineligible for checkpoint inhibitors (including PD-1 or PD-L1 inhibitors).
    3. Failed or have been ineligible for enfortumab vedotin.
    4. Have no known life-prolonging therapy available

Exclusion Criteria: General

  1. Participant with known symptomatic brain metastases requiring > 10 mg/day of prednisolone (or its equivalent). Participants with previously diagnosed brain metastases are eligible if they have completed their treatment, have recovered from the acute effects of radiation therapy or surgery prior to the start of ACR-368 treatment, fulfill the steroid requirement for these metastases, and are neurologically stable based on central nervous system imaging ≥ 4 weeks after treatment.
  2. Participant had a failure to recover from the reversible effects of prior anti-cancer therapy, as follows:

    a. Endocrine events from prior immunotherapy at Grade > 2. b. Neuropathy events from prior cytotoxic therapies at Grade > 2. c. All other reversible effects of prior anti-cancer therapy (except alopecia) at Grade >1 or Baseline.

  3. Participant had systemic therapy or radiation therapy within 2 weeks prior to the first dose of study drug.
  4. Participants has known human immunodeficiency virus, hepatitis B, or hepatitis C infection that is considered uncontrolled based on the criteria included in Appendix 2.
  5. Participant has a history of clinically meaningful coagulopathy, bleeding diathesis.
  6. Participant has cardiovascular disease, defined as:

    1. Uncontrolled hypertension defined as blood pressure > 160/90 mmHg at Screening confirmed by repeat (medication permitted).
    2. History of torsades de pointes, significant Screening electrocardiogram (ECG) abnormalities, including ventricular rhythm disturbances, unstable cardiac arrhythmia requiring medication, pathologic symptomatic bradycardia, left bundle branch block, second degree atrioventricular (AV) block type II, third degree AV block, Grade ≥ 2 bradycardia, uncorrected hypokalemia not amenable to correction, congenital long QT syndrome, prolonged QT interval due to medications, corrected QT (QTc) > 450 msec (for men) or > 470 msec (for women).
    3. Symptomatic heart failure (per New York Heart Association guidelines; (Caraballo, 2019), unstable angina, myocardial infarction, severe cardiovascular disease (ejection fraction < 20%, transient ischemic attack, or cerebrovascular accident within 6 months of Day 1).
  7. Participant has a history of major surgery within 4 weeks of Screening.
  8. Participant has a history of bowel obstruction requiring decompression through a nasogastric tube within 8 weeks of Screening. Participants has signs or symptoms of intestinal obstruction, which include nausea, vomiting, and objective radiologic finding of bowel obstruction.
  9. Participant has taken a prior cell cycle CHK1 inhibitor, including ACR-368

Tumor Specific Exclusion Criteria

For Ovarian Carcinoma:

  1. Participant has non-epithelial carcinoma, clear-cell, mucinous, germ-cell, low-grade serous, or low-grade endometrioid carcinoma.
  2. Participant has a history of clinically meaningful ascites, defined as a history of paracentesis or thoracentesis within 4 weeks of Screening.
  3. Participant has a history of active inflammatory bowel disease within 2 years prior to Screening.
  4. Participant has a history of bowel perforation, fistula, necrosis, or leak within 8 weeks of Screening.

For Endometrial Adenocarcinoma:

  1. Participant has low-grade endometrioid carcinoma.
  2. Participant has mesenchymal tumors of the uterus.
  3. Participant has a history of clinically meaningful ascites, defined as a history of paracentesis or thoracentesis within 4 weeks of Screening.

For Urothelial Carcinoma:

  1. Participant has sarcoma, carcinosarcoma, melanoma, or lymphoma of the bladder.
  2. Participant has not received a previous platinum-based regimen.
  3. Participant has small cell or neuroendocrine histology.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05548296


Contacts
Layout table for location contacts
Contact: Dominic Lai, MD 617-207-8976 ACR-368-201ClinicalTrial@acrivon.com
Contact: Laura Massey 617-207-8975 ACR-368-201ClinicalTrial@acrivon.com

Locations
Layout table for location information
United States, Alabama
University of South Alabama Mitchell Cancer Institute Recruiting
Mobile, Alabama, United States, 36604
Contact: Stafanie White         
Principal Investigator: Jennifer Scalici, MD         
United States, Connecticut
Yale Cancer Center Recruiting
New Haven, Connecticut, United States, 06520
Contact: Ingrid Palma         
Principal Investigator: Joseph W. Kim, MD         
United States, Maryland
American Oncology Partners of Maryland PA Recruiting
Bethesda, Maryland, United States, 20817
Contact: Natalie Bongiorno         
Principal Investigator: Mark Goldstein, MD         
National Institutes of Health, Clinical Center Recruiting
Bethesda, Maryland, United States, 20892
Contact: Ann McCoy, RN         
Principal Investigator: Jung-Min Lee, MD         
United States, New York
Memorial Sloan-Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Chrisann Kyi, MD         
Principal Investigator: Jonathan Rosenberg, MD         
United States, Ohio
Gabrail Cancer Center Recruiting
Canton, Ohio, United States, 44718
Contact: Kim Roby         
Principal Investigator: Nashat Gabrail, MD         
United States, Texas
University of Texas, MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Nicholas Hanan         
Principal Investigator: Funda Meric-Bernstam, MD         
United States, Washington
Summit Cancer Center Recruiting
Spokane, Washington, United States, 99208
Contact: Monika Chaudhry         
Contact: Monika         
Principal Investigator: Arvind Chaudhry, MD, PhD         
Sponsors and Collaborators
Acrivon Therapeutics
GOG Foundation
Investigators
Layout table for investigator information
Principal Investigator: Jung-Min Lee, MD National Cancer Institute (NCI)
Layout table for additonal information
Responsible Party: Acrivon Therapeutics
ClinicalTrials.gov Identifier: NCT05548296    
Other Study ID Numbers: ACR-368-201 (GOG 3082)
First Posted: September 21, 2022    Key Record Dates
Last Update Posted: January 26, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by Acrivon Therapeutics:
Urothelial Carcinoma
Bladder Cancer
Urinary Bladder Neoplasm
Urologic Neoplasm
Urogenital Neoplasm
Endometrial Cancer
Endometrial Neoplasm
Ovarian Cancer
Ovarian Neoplasm
Low dose gemcitabine
Platinum-resistant Ovarian Carcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Adenocarcinoma
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Carcinoma, Transitional Cell
Uterine Neoplasms
Endometrial Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Uterine Diseases
Gemcitabine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs